Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HS-10518 in Healthy Premenopausal Females
NCT07264192Phase 1Completed
- Sponsor
- West China Second University Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of merigolix in female infertility (6 arms), sponsored by West China Second University Hospital. Primary endpoints: Incidence of Adverse Events at Day 21, Number of Participants with Clinically Significant Changes in Laboratory Parameters at Day 16 and 1 more. Started Mar 2025; status: completed.
02
Drugs
merigolix
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT07264192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264192.